1. Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma
- Author
-
Chen, Ru, Dawson, David W, Pan, Sheng, Ottenhof, Niki A, de Wilde, Roeland F, Wolfgang, Christopher L, May, Damon H, Crispin, David A, Lai, Lisa A, Lay, Anna R, Waghray, Meghna, Wang, Shouli, McIntosh, Martin W, Simeone, Diane M, Maitra, Anirban, and Brentnall, Teresa A
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Pancreatic Cancer ,Orphan Drug ,Digestive Diseases ,Rare Diseases ,Clinical Research ,2.1 Biological and endogenous factors ,Adenocarcinoma ,Carcinoma ,Pancreatic Ductal ,Cell Line ,Tumor ,Female ,Humans ,Male ,Middle Aged ,Neoplasm Proteins ,Pancreatic Neoplasms ,Proteomics ,Survival Analysis ,Clinical Sciences ,Pathology ,Clinical sciences - Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with a dismal prognosis. However, while most patients die within the first year of diagnosis, very rarely, a few patients can survive for >10 years. Better understanding the molecular characteristics of the pancreatic adenocarcinomas from these very-long-term survivors (VLTS) may provide clues for personalized medicine and improve current pancreatic cancer treatment. To extend our previous investigation, we examined the proteomes of individual pancreas tumor tissues from a group of VLTS patients (survival ≥10 years) and short-term survival patients (STS, survival
- Published
- 2015